Longitudinal therapy monitoring of ALK-positive lung cancer by combined copy number and targeted mutation profiling of cell-free DNA

Background - Targeted therapies (TKI) have improved the prognosis of ALK-rearranged lung cancer (ALK+ NSCLC), but clinical courses vary widely. Early identification and molecular characterisation of treatment failure have key importance for subsequent therapies. We performed copy number variation (C...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Dietz, Steffen (VerfasserIn) , Christopoulos, Petros (VerfasserIn) , Yuan, Zhao (VerfasserIn) , Angeles, Arlou Kristina J. (VerfasserIn) , Gu, Lisa (VerfasserIn) , Volckmar, Anna-Lena (VerfasserIn) , Ogrodnik, Simon (VerfasserIn) , Janke, Florian (VerfasserIn) , Dalle Fratte, Chiara (VerfasserIn) , Zemojtel, Tomasz (VerfasserIn) , Schneider, Marc (VerfasserIn) , Kazdal, Daniel (VerfasserIn) , Endris, Volker (VerfasserIn) , Meister, Michael (VerfasserIn) , Muley, Thomas (VerfasserIn) , Cecchin, Erika (VerfasserIn) , Reck, Martin (VerfasserIn) , Schlesner, Matthias (VerfasserIn) , Thomas, Michael (VerfasserIn) , Stenzinger, Albrecht (VerfasserIn) , Sültmann, Holger (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: 9 November 2020
In: EBioMedicine
Year: 2020, Jahrgang: 62, Heft: 12, Pages: 1-10
ISSN:2352-3964
DOI:10.1016/j.ebiom.2020.103103
Online-Zugang:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1016/j.ebiom.2020.103103
Verlag, lizenzpflichtig, Volltext: https://www.sciencedirect.com/science/article/pii/S2352396420304795
Volltext
Verfasserangaben:Steffen Dietz, Petros Christopoulos, Zhao Yuan, Arlou Kristina Angeles, Lisa Gu, Anna-Lena Volckmar, Simon J. Ogrodnik, Florian Janke, Chiara Dalle Fratte, Tomasz Zemojtel, Marc A. Schneider, Daniel Kazdal, Volker Endris, Michael Meister, Thomas Muley, Erika Cecchin, Martin Reck, Matthias Schlesner, Michael Thomas, Albrecht Stenzinger, Holger Sültmann

MARC

LEADER 00000caa a2200000 c 4500
001 1788522419
003 DE-627
005 20230426162739.0
007 cr uuu---uuuuu
008 220204s2020 xx |||||o 00| ||eng c
024 7 |a 10.1016/j.ebiom.2020.103103  |2 doi 
035 |a (DE-627)1788522419 
035 |a (DE-599)KXP1788522419 
035 |a (OCoLC)1341441371 
040 |a DE-627  |b ger  |c DE-627  |e rda 
041 |a eng 
084 |a 33  |2 sdnb 
100 1 |a Dietz, Steffen  |d 1988-  |e VerfasserIn  |0 (DE-588)1148996575  |0 (DE-627)1009298062  |0 (DE-576)496511556  |4 aut 
245 1 0 |a Longitudinal therapy monitoring of ALK-positive lung cancer by combined copy number and targeted mutation profiling of cell-free DNA  |c Steffen Dietz, Petros Christopoulos, Zhao Yuan, Arlou Kristina Angeles, Lisa Gu, Anna-Lena Volckmar, Simon J. Ogrodnik, Florian Janke, Chiara Dalle Fratte, Tomasz Zemojtel, Marc A. Schneider, Daniel Kazdal, Volker Endris, Michael Meister, Thomas Muley, Erika Cecchin, Martin Reck, Matthias Schlesner, Michael Thomas, Albrecht Stenzinger, Holger Sültmann 
264 1 |c 9 November 2020 
300 |a 10 
336 |a Text  |b txt  |2 rdacontent 
337 |a Computermedien  |b c  |2 rdamedia 
338 |a Online-Ressource  |b cr  |2 rdacarrier 
500 |a Gesehen am 08.02.2022 
520 |a Background - Targeted therapies (TKI) have improved the prognosis of ALK-rearranged lung cancer (ALK+ NSCLC), but clinical courses vary widely. Early identification and molecular characterisation of treatment failure have key importance for subsequent therapies. We performed copy number variation (CNV) profiling and targeted panel sequencing from cell-free DNA (cfDNA) to monitor ALK+ NSCLC. - Methods - 271 longitudinal plasma DNA samples from 73 patients with TKI-treated metastatic ALK+ NSCLC were analysed by capture-based targeted (average coverage 4,100x), and shallow whole genome sequencing (sWGS, 0.5x). Mutations were called using standard algorithms. CNVs were quantified using the trimmed median absolute deviation from copy number neutrality (t-MAD). - Findings - cfDNA mutations were identified in 58% of patients. They included several potentially actionable alterations, e.g. in the genes BRAF, ERBB2, and KIT. sWGS detected CNVs in 18% of samples, compared to 6% using targeted sequencing. Several of the CNVs included potentially druggable targets, such as regions harboring EGFR, ERBB2, and MET. Circulating tumour DNA (ctDNA) mutations and t-MAD scores increased during treatment, correlated with markers of higher molecular risk, such as the EML4-ALK variant 3 and/or TP53 mutations, and were associated with shorter patient survival. Importantly, t-MAD scores reflected the tumour remission status in serial samples similar to mutant ctDNA allele frequencies, and increased with disease progression in 79% (34/43) of cases, including those without detectable single nucleotide variant (SNV). - Interpretation - Combined copy number and targeted mutation profiling could improve monitoring of ALK+ NSCLC. Potential advantages include the identification of treatment failure, in particular for patients without detectable mutations, and broader detection of genomic changes acquired during therapy, especially in later treatment lines and in high-risk patients. - Funding - This work was supported by the German Center for Lung Research (DZL), by the German Cancer Consortium (DKTK), by the Heidelberg Center for Personalized Oncology at the German Cancer Research Center (DKFZ-HIPO), and by Roche Sequencing Solutions (Pleasanton, CA, USA). 
650 4 |a ALK 
650 4 |a Liquid biopsy 
650 4 |a Non-small cell lung cancer 
650 4 |a Therapy monitoring 
700 1 |a Christopoulos, Petros  |d 1977-  |e VerfasserIn  |0 (DE-588)138659702  |0 (DE-627)604886756  |0 (DE-576)308488067  |4 aut 
700 1 |a Yuan, Zhao  |d 1988-  |e VerfasserIn  |0 (DE-588)1251323790  |0 (DE-627)1788800192  |4 aut 
700 1 |a Angeles, Arlou Kristina J.  |d 1988-  |e VerfasserIn  |0 (DE-588)1197831541  |0 (DE-627)167974416X  |4 aut 
700 1 |a Gu, Lisa  |d 1996-  |e VerfasserIn  |0 (DE-588)1208775375  |0 (DE-627)1695611195  |4 aut 
700 1 |a Volckmar, Anna-Lena  |d 1984-  |e VerfasserIn  |0 (DE-588)173874916  |0 (DE-627)698776666  |0 (DE-576)134713478  |4 aut 
700 1 |a Ogrodnik, Simon  |e VerfasserIn  |0 (DE-588)1181809037  |0 (DE-627)1662371349  |4 aut 
700 1 |a Janke, Florian  |d 1991-  |e VerfasserIn  |0 (DE-588)1216211086  |0 (DE-627)1727474686  |4 aut 
700 1 |a Dalle Fratte, Chiara  |e VerfasserIn  |4 aut 
700 1 |a Zemojtel, Tomasz  |d 1975-  |e VerfasserIn  |0 (DE-588)130248460  |0 (DE-627)495830097  |0 (DE-576)189544562  |4 aut 
700 1 |a Schneider, Marc  |d 1982-  |e VerfasserIn  |0 (DE-588)140634401  |0 (DE-627)620239948  |0 (DE-576)319208095  |4 aut 
700 1 |a Kazdal, Daniel  |d 1983-  |e VerfasserIn  |0 (DE-588)114929650X  |0 (DE-627)1009614088  |0 (DE-576)496635867  |4 aut 
700 1 |a Endris, Volker  |e VerfasserIn  |0 (DE-588)1063753686  |0 (DE-627)812590961  |0 (DE-576)422898198  |4 aut 
700 1 |a Meister, Michael  |e VerfasserIn  |0 (DE-588)1078792046  |0 (DE-627)839461402  |0 (DE-576)451890108  |4 aut 
700 1 |a Muley, Thomas  |e VerfasserIn  |0 (DE-588)1056885432  |0 (DE-627)794179169  |0 (DE-576)16759284X  |4 aut 
700 1 |a Cecchin, Erika  |e VerfasserIn  |4 aut 
700 1 |a Reck, Martin  |d 1965-  |e VerfasserIn  |0 (DE-588)137678711  |0 (DE-627)594837413  |0 (DE-576)30483873X  |4 aut 
700 1 |a Schlesner, Matthias  |d 1978-  |e VerfasserIn  |0 (DE-588)138455201  |0 (DE-627)602593867  |0 (DE-576)307654656  |4 aut 
700 1 |a Thomas, Michael  |e VerfasserIn  |0 (DE-588)1054438781  |0 (DE-627)79152213X  |0 (DE-576)41027089X  |4 aut 
700 1 |a Stenzinger, Albrecht  |e VerfasserIn  |0 (DE-588)139606106  |0 (DE-627)703395238  |0 (DE-576)312432755  |4 aut 
700 1 |a Sültmann, Holger  |d 1962-  |e VerfasserIn  |0 (DE-588)172777291  |0 (DE-627)697708144  |0 (DE-576)133633926  |4 aut 
773 0 8 |i Enthalten in  |t EBioMedicine  |d Amsterdam [u.a.] : Elsevier, 2014  |g 62(2020), 12, Artikel-ID 103103, Seite 1-10  |h Online-Ressource  |w (DE-627)802540074  |w (DE-600)2799017-5  |w (DE-576)416965725  |x 2352-3964  |7 nnas  |a Longitudinal therapy monitoring of ALK-positive lung cancer by combined copy number and targeted mutation profiling of cell-free DNA 
773 1 8 |g volume:62  |g year:2020  |g number:12  |g elocationid:103103  |g pages:1-10  |g extent:10  |a Longitudinal therapy monitoring of ALK-positive lung cancer by combined copy number and targeted mutation profiling of cell-free DNA 
856 4 0 |u https://doi.org/10.1016/j.ebiom.2020.103103  |x Verlag  |x Resolving-System  |z lizenzpflichtig  |3 Volltext 
856 4 0 |u https://www.sciencedirect.com/science/article/pii/S2352396420304795  |x Verlag  |z lizenzpflichtig  |3 Volltext 
951 |a AR 
992 |a 20220204 
993 |a Article 
994 |a 2020 
998 |g 172777291  |a Sültmann, Holger  |m 172777291:Sültmann, Holger  |d 50000  |e 50000PS172777291  |k 0/50000/  |p 21  |y j 
998 |g 139606106  |a Stenzinger, Albrecht  |m 139606106:Stenzinger, Albrecht  |d 910000  |d 912000  |e 910000PS139606106  |e 912000PS139606106  |k 0/910000/  |k 1/910000/912000/  |p 20 
998 |g 1054438781  |a Thomas, Michael  |m 1054438781:Thomas, Michael  |d 50000  |d 910000  |d 950000  |d 950900  |e 50000PT1054438781  |e 910000PT1054438781  |e 950000PT1054438781  |e 950900PT1054438781  |k 0/50000/  |k 0/910000/  |k 1/910000/950000/  |k 2/910000/950000/950900/  |p 19 
998 |g 138455201  |a Schlesner, Matthias  |m 138455201:Schlesner, Matthias  |d 50000  |e 50000PS138455201  |k 0/50000/  |p 18 
998 |g 1056885432  |a Muley, Thomas  |m 1056885432:Muley, Thomas  |d 910000  |d 950000  |d 950900  |e 910000PM1056885432  |e 950000PM1056885432  |e 950900PM1056885432  |k 0/910000/  |k 1/910000/950000/  |k 2/910000/950000/950900/  |p 15 
998 |g 1078792046  |a Meister, Michael  |m 1078792046:Meister, Michael  |d 910000  |d 950000  |d 950900  |e 910000PM1078792046  |e 950000PM1078792046  |e 950900PM1078792046  |k 0/910000/  |k 1/910000/950000/  |k 2/910000/950000/950900/  |p 14 
998 |g 1063753686  |a Endris, Volker  |m 1063753686:Endris, Volker  |d 910000  |d 912000  |e 910000PE1063753686  |e 912000PE1063753686  |k 0/910000/  |k 1/910000/912000/  |p 13 
998 |g 114929650X  |a Kazdal, Daniel  |m 114929650X:Kazdal, Daniel  |d 910000  |d 912000  |e 910000PK114929650X  |e 912000PK114929650X  |k 0/910000/  |k 1/910000/912000/  |p 12 
998 |g 140634401  |a Schneider, Marc  |m 140634401:Schneider, Marc  |d 50000  |d 910000  |d 950000  |d 950900  |e 50000PS140634401  |e 910000PS140634401  |e 950000PS140634401  |e 950900PS140634401  |k 0/50000/  |k 0/910000/  |k 1/910000/950000/  |k 2/910000/950000/950900/  |p 11 
998 |g 1216211086  |a Janke, Florian  |m 1216211086:Janke, Florian  |d 50000  |e 50000PJ1216211086  |k 0/50000/  |p 8 
998 |g 173874916  |a Volckmar, Anna-Lena  |m 173874916:Volckmar, Anna-Lena  |d 910000  |d 912000  |e 910000PV173874916  |e 912000PV173874916  |k 0/910000/  |k 1/910000/912000/  |p 6 
998 |g 1208775375  |a Gu, Lisa  |m 1208775375:Gu, Lisa  |d 50000  |e 50000PG1208775375  |k 0/50000/  |p 5 
998 |g 1251323790  |a Yuan, Zhao  |m 1251323790:Yuan, Zhao  |d 140000  |e 140000PY1251323790  |k 0/140000/  |p 3 
998 |g 138659702  |a Christopoulos, Petros  |m 138659702:Christopoulos, Petros  |d 50000  |d 910000  |d 950000  |d 950900  |e 50000PC138659702  |e 910000PC138659702  |e 950000PC138659702  |e 950900PC138659702  |k 0/50000/  |k 0/910000/  |k 1/910000/950000/  |k 2/910000/950000/950900/  |p 2 
999 |a KXP-PPN1788522419  |e 4051309916 
BIB |a Y 
SER |a journal 
JSO |a {"relHost":[{"language":["eng"],"recId":"802540074","disp":"Longitudinal therapy monitoring of ALK-positive lung cancer by combined copy number and targeted mutation profiling of cell-free DNAEBioMedicine","type":{"bibl":"periodical","media":"Online-Ressource"},"pubHistory":["Volume 1 (2014)-"],"title":[{"title_sort":"EBioMedicine","title":"EBioMedicine"}],"origin":[{"dateIssuedKey":"2014","publisherPlace":"Amsterdam [u.a.]","publisher":"Elsevier","dateIssuedDisp":"2014-"}],"note":["Gesehen am 28.05.2020"],"part":{"text":"62(2020), 12, Artikel-ID 103103, Seite 1-10","volume":"62","year":"2020","pages":"1-10","extent":"10","issue":"12"},"id":{"eki":["802540074"],"issn":["2352-3964"],"zdb":["2799017-5"]},"physDesc":[{"extent":"Online-Ressource"}]}],"note":["Gesehen am 08.02.2022"],"physDesc":[{"extent":"10 S."}],"type":{"bibl":"article-journal","media":"Online-Ressource"},"id":{"doi":["10.1016/j.ebiom.2020.103103"],"eki":["1788522419"]},"language":["eng"],"title":[{"title":"Longitudinal therapy monitoring of ALK-positive lung cancer by combined copy number and targeted mutation profiling of cell-free DNA","title_sort":"Longitudinal therapy monitoring of ALK-positive lung cancer by combined copy number and targeted mutation profiling of cell-free DNA"}],"person":[{"role":"aut","display":"Dietz, Steffen","given":"Steffen","family":"Dietz"},{"family":"Christopoulos","display":"Christopoulos, Petros","given":"Petros","role":"aut"},{"role":"aut","display":"Yuan, Zhao","given":"Zhao","family":"Yuan"},{"role":"aut","family":"Angeles","display":"Angeles, Arlou Kristina J.","given":"Arlou Kristina J."},{"role":"aut","family":"Gu","display":"Gu, Lisa","given":"Lisa"},{"role":"aut","display":"Volckmar, Anna-Lena","given":"Anna-Lena","family":"Volckmar"},{"given":"Simon","display":"Ogrodnik, Simon","family":"Ogrodnik","role":"aut"},{"role":"aut","family":"Janke","given":"Florian","display":"Janke, Florian"},{"role":"aut","given":"Chiara","display":"Dalle Fratte, Chiara","family":"Dalle Fratte"},{"role":"aut","display":"Zemojtel, Tomasz","given":"Tomasz","family":"Zemojtel"},{"family":"Schneider","display":"Schneider, Marc","given":"Marc","role":"aut"},{"family":"Kazdal","given":"Daniel","display":"Kazdal, Daniel","role":"aut"},{"role":"aut","display":"Endris, Volker","given":"Volker","family":"Endris"},{"role":"aut","display":"Meister, Michael","given":"Michael","family":"Meister"},{"family":"Muley","display":"Muley, Thomas","given":"Thomas","role":"aut"},{"role":"aut","family":"Cecchin","given":"Erika","display":"Cecchin, Erika"},{"role":"aut","family":"Reck","given":"Martin","display":"Reck, Martin"},{"role":"aut","family":"Schlesner","given":"Matthias","display":"Schlesner, Matthias"},{"family":"Thomas","given":"Michael","display":"Thomas, Michael","role":"aut"},{"role":"aut","family":"Stenzinger","display":"Stenzinger, Albrecht","given":"Albrecht"},{"role":"aut","given":"Holger","display":"Sültmann, Holger","family":"Sültmann"}],"recId":"1788522419","origin":[{"dateIssuedDisp":"9 November 2020","dateIssuedKey":"2020"}],"name":{"displayForm":["Steffen Dietz, Petros Christopoulos, Zhao Yuan, Arlou Kristina Angeles, Lisa Gu, Anna-Lena Volckmar, Simon J. Ogrodnik, Florian Janke, Chiara Dalle Fratte, Tomasz Zemojtel, Marc A. Schneider, Daniel Kazdal, Volker Endris, Michael Meister, Thomas Muley, Erika Cecchin, Martin Reck, Matthias Schlesner, Michael Thomas, Albrecht Stenzinger, Holger Sültmann"]}} 
SRT |a DIETZSTEFFLONGITUDIN9202